Cann Group Limited
CAN.AX
Australian Securities Exchange0.00
AUD
- -
- -
Cann Group Limited
CAN.AX
(Australian Securities Exchange)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Cann Group Limited (ASX:CAN), founded in 2014 and headquartered in Port Melbourne, Victoria, Australia, operates as an Australian-based B2B medicinal cannabis company specializing in the breeding, cultivation, manufacturing, and supply of pharmaceutical-grade cannabis products for medicinal and research purposes; its core offerings include dried flower and oil products, active pharmaceutical ingredients (APIs), extracts, and proprietary brands such as Satipharm featuring patent-protected lipophilic capsule delivery systems for cannabinoids and Botanitech providing a diverse range of affordable, high-quality formulations. The company maintains world-class research, cultivation, and GMP-certified manufacturing facilities in Bundoora (northern Melbourne) and a state-of-the-art large-scale cultivation and GMP facility near Mildura, Victoria, supporting operations primarily in Australia with approved exports to Europe and global markets. Cann Group holds pioneering Australian licenses including the first Cannabis Research Licence (issued February 2017) and Medicinal Cannabis Cultivation Licence (March 2017) from the Office of Drug Control, positioning it as a leader in plant genetics, breeding, extraction, analysis, and production techniques for treating various diseases and medical conditions. In late 2025, the company executed a major debt restructure reducing liabilities by 81% through National Australia Bank forgiveness of $54.7 million (settling $70 million in loans for $15.3 million), alongside a $9 million capital raise via institutional placement and Share Purchase Plan (with attached options potentially yielding $31.3 million), a new $14.5 million loan facility maturing in two years, board changes appointing Mike Ryan as Chairman replacing interim chair Doug Rathbone, and FY26 guidance projecting $17 million revenue (50% growth) and positive EBITDA of $0.3-0.7 million.